Skip to main content
Home
Publications Portal
Explore Publications
Request a Poster From Supernus
Research & Development
Commercial Products
Investor Relations
Request Posters
Webform - Request a Poster
Requestee Name
Requestee Email
Request Poster(s) Related to:
- Select -
Qelbree
Available Posters (SPN-810)
An Electronic Observer-Reported Outcomes Instrument (IA Diary) to Measure Impulsive Aggression in Children With Optimally Treated Attention-Deficit/Hyperactivity Disorder
Battery of Reproductive Toxicology Studies Supporting the Safety of a Dopamine Receptor Antagonist, Molindone
Efficacy and Safety of Extended-Release Molindone (SPN-810) to Treat Impulsive Aggression in Children Being Optimally Treated for Their Attention-Deficit/Hyperactivity Disorder: Phase 2b and Open-Label Extension Results
Long-Term Efficacy and Safety of Extended-Release Molindone (SPN-810) to Manage Impulsive Aggression in Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
Available Posters (Qelbree)
Assessment of Pediatric Weight and Height Trajectories During Long-term Viloxazine ER (Qelbree®) Treatment: Interim Results from an Open-label Extension Trial in ADHD
Efficacy of viloxazine ER in treating defiant/aggressive and risky decision-making behaviors in children and adolescents with ADHD
Qelbree® (Viloxazine ER) Efficacy in Adults with ADHD Inattentive or Combined Presentations
Efficacy of Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Adults with Attention-Deficit/Hyperactivity Disorder: Results From an Open-Label Extension
Characterization of Viloxazine’s Serotonergic Effects at Doses Relevant for ADHD Treatment
Assessment of Serotonergic Effects of Viloxazine in Cynomolgus Monkeys Using PET Imaging with the [11C]CIMBI-36 Serotonin Receptor (5-HT2A/2C) Agonist Radioligand
Viloxazine Induces Dose-Dependent Increases in Interstitial Levels of Norepinephrine, Dopamine, and Serotonin in Rat Medial Prefrontal Cortex
Interim Analysis of Efficacy During Long-Term Treatment with Viloxazine Extended-Release Capsules (Qelbree®) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
The Impact of Viloxazine Extended-Release Capsules (Qelbree®) on Executive Function Assessed via the BRIEF-A in an Open-Label Extension Safety Trial of Adults with Attention-Deficit/Hyperactivity Disorder
Available Posters (Oxtellar XR)
Adherence and Resource Utilization with Extended-Release Oxtellar XR® or Immediate-Release Oxcarbazepine (OXC-IR) Treatment in Clinical Practice: A Standardized Case Record Review
Clinical Outcomes of Treatment with Oxtellar XR® or Immediate-Release Oxcarbazepine (OXC-IR) in Typical Care Settings: A Standardized Case Record Review
Efficacy and Safety of Extended-release Oxcarbazepine (Oxtellar XR™) as Adjunctive Therapy in Patients with Refractory Partial-onset Seizures: A Randomized Controlled Trial
Efficacy and Tolerability of Oxtellar XR™, A Novel Once-Daily, Extended-Release Formulation of Oxcarbazepine, As Adjunctive Treatment of Refractory Partial Seizures in a North American Subpopulation
Licarbazepine (LCBZ) Pharmacokinetics with Once-Daily Oxtellar XR®
Long-Term, Open-Label Safety and Tolerability Study of Oxtellar XR™, A Novel Once-Daily, Extended-Release Oxcarbazepine Formulation, as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures
Oxcarbazepine Pharmacokinetics of Extended-Release Once-Daily SPN-804 (Oxtellar XR®) in the Elderly
Pharmacokinetic-Pharmacodynamic Analysis of Extended-Release Once-Daily Oxcarbazepine Formulation SPN-804 (Oxtellar XR®) in Adults with Epilepsy
Steady-State Licarbazepine (LCBZ) Pharmacokinetic Profile with Once-Daily Dosing of Extended-Release Oxtellar XR®
Supernus Pharmaceuticals: Novel Extended-Release Technology Concepts Advancing Patient Therapy in Epilepsy
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
